Clinical trial SGNTUC-028 - HER2CLIMB-05
A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Seagen |
| EudraCT Identifier | 2021-002491-39 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05132582 |
| Last update |